Our study used evidence from a recent randomized controlled trial of patients with intermediate- and high-risk bladder cancer, the BOXIT trial (bladder COX-2 [cyclo-oxygenase-2] inhibition trial). The gene discussed is PTGS2; the disease is urinary bladder cancer.